CN113717226B - 含双磷酸结构的七甲川花菁类小分子化合物和制备方法及应用 - Google Patents
含双磷酸结构的七甲川花菁类小分子化合物和制备方法及应用 Download PDFInfo
- Publication number
- CN113717226B CN113717226B CN202110858109.9A CN202110858109A CN113717226B CN 113717226 B CN113717226 B CN 113717226B CN 202110858109 A CN202110858109 A CN 202110858109A CN 113717226 B CN113717226 B CN 113717226B
- Authority
- CN
- China
- Prior art keywords
- heptamethine cyanine
- solution
- organic solvent
- compound
- small molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 27
- GDIYMWAMJKRXRE-UHFFFAOYSA-N (2z)-2-[(2e)-2-[2-chloro-3-[(z)-2-(1,3,3-trimethylindol-1-ium-2-yl)ethenyl]cyclohex-2-en-1-ylidene]ethylidene]-1,3,3-trimethylindole Chemical compound CC1(C)C2=CC=CC=C2N(C)C1=CC=C1C(Cl)=C(C=CC=2C(C3=CC=CC=C3[N+]=2C)(C)C)CCC1 GDIYMWAMJKRXRE-UHFFFAOYSA-N 0.000 title claims abstract description 15
- 239000002253 acid Substances 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims abstract description 11
- 230000005855 radiation Effects 0.000 claims abstract description 18
- -1 heptamethine cyanine compound Chemical class 0.000 claims abstract description 16
- 206010065687 Bone loss Diseases 0.000 claims abstract description 12
- 230000002265 prevention Effects 0.000 claims abstract description 3
- 210000000988 bone and bone Anatomy 0.000 claims description 28
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 21
- 239000000243 solution Substances 0.000 claims description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 15
- 238000003756 stirring Methods 0.000 claims description 12
- 238000006243 chemical reaction Methods 0.000 claims description 11
- 239000003960 organic solvent Substances 0.000 claims description 11
- 230000008685 targeting Effects 0.000 claims description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical group C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 5
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 4
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical group ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 claims description 4
- 239000012043 crude product Substances 0.000 claims description 4
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 claims description 4
- 125000000524 functional group Chemical group 0.000 claims description 4
- 239000003223 protective agent Substances 0.000 claims description 4
- DKIDEFUBRARXTE-UHFFFAOYSA-N 3-mercaptopropanoic acid Chemical compound OC(=O)CCS DKIDEFUBRARXTE-UHFFFAOYSA-N 0.000 claims description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 239000012190 activator Substances 0.000 claims description 3
- 239000007853 buffer solution Substances 0.000 claims description 3
- 238000003333 near-infrared imaging Methods 0.000 claims description 3
- 238000004262 preparative liquid chromatography Methods 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- 239000002994 raw material Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- 229910019142 PO4 Inorganic materials 0.000 claims description 2
- 230000003213 activating effect Effects 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000012046 mixed solvent Substances 0.000 claims description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 2
- 239000010452 phosphate Substances 0.000 claims description 2
- 238000000967 suction filtration Methods 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 5
- 238000009472 formulation Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000019155 Radiation injury Diseases 0.000 abstract description 3
- 230000008901 benefit Effects 0.000 abstract description 2
- 238000009825 accumulation Methods 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 210000000689 upper leg Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 5
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000000799 fluorescence microscopy Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- 210000001835 viscera Anatomy 0.000 description 4
- 238000000862 absorption spectrum Methods 0.000 description 3
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 3
- 239000004327 boric acid Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002189 fluorescence spectrum Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 239000012224 working solution Substances 0.000 description 3
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000011981 development test Methods 0.000 description 2
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 210000000963 osteoblast Anatomy 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000003537 radioprotector Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 229940122361 Bisphosphonate Drugs 0.000 description 1
- FRPHFZCDPYBUAU-UHFFFAOYSA-N Bromocresolgreen Chemical compound CC1=C(Br)C(O)=C(Br)C=C1C1(C=2C(=C(Br)C(O)=C(Br)C=2)C)C2=CC=CC=C2S(=O)(=O)O1 FRPHFZCDPYBUAU-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000208125 Nicotiana Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ONBIUAZBGHXJDM-UHFFFAOYSA-J bismuth;potassium;tetraiodide Chemical compound [K+].[I-].[I-].[I-].[I-].[Bi+3] ONBIUAZBGHXJDM-UHFFFAOYSA-J 0.000 description 1
- 150000004663 bisphosphonates Chemical group 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000025084 cell cycle arrest Effects 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000037319 collagen production Effects 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000005865 ionizing radiation Effects 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000005025 nuclear technology Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- DHRLEVQXOMLTIM-UHFFFAOYSA-N phosphoric acid;trioxomolybdenum Chemical compound O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.O=[Mo](=O)=O.OP(O)(O)=O DHRLEVQXOMLTIM-UHFFFAOYSA-N 0.000 description 1
- 238000001126 phototherapy Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000001308 synthesis method Methods 0.000 description 1
- 210000002303 tibia Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000001392 ultraviolet--visible--near infrared spectroscopy Methods 0.000 description 1
- 210000003932 urinary bladder Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/572—Five-membered rings
- C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K11/00—Luminescent, e.g. electroluminescent, chemiluminescent materials
- C09K11/06—Luminescent, e.g. electroluminescent, chemiluminescent materials containing organic luminescent materials
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
- C09K2211/00—Chemical nature of organic luminescent or tenebrescent compounds
- C09K2211/10—Non-macromolecular compounds
- C09K2211/1018—Heterocyclic compounds
- C09K2211/1025—Heterocyclic compounds characterised by ligands
- C09K2211/1029—Heterocyclic compounds characterised by ligands containing one nitrogen atom as the heteroatom
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Toxicology (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及含双磷酸结构的七甲川花菁类小分子化合物和制备方法及应用,本发明在七甲川花菁类小分子的共轭母体结构中引入具有骨靶向特性的双磷酸结构,构建了一种高选择性识别骨组织、近红外荧光成像的七甲川花菁类小分子化合物。所述七甲川花菁类化合物对辐射诱导的骨丢失具有良好的防治功能,对预防辐射损伤具有潜在意义。所述化合物具有制备方法简单,以及成本低的优点。
Description
技术领域
本发明涉及一种七甲川花菁类化合物,特别涉及一种七甲川花菁类小分子化合物和制备方法及应用。
背景技术
随着核能与核技术应用的发展,人们遭受辐射损伤的潜在性风险大大增加,包括核辐射事故、宇宙空间探索、癌症治疗、放射诊断和辐射加工等领域。相关研究表明,辐射对机体损伤的临床症状表现为造血功能障碍,其中辐射损伤多以骨髓损伤更为常见。骨髓作为人体内的造血干细胞的主要来源,位于长骨的髓腔及所有骨松质内,是对电离辐射的细胞毒性反应最敏感的器官;此外,辐射能减少成骨细胞的增殖和分化,诱导细胞周期停滞,减少胶原蛋白的生成,损害或杀死成骨细胞,并抑制骨形成,导致骨丢失。因此,寻求一种高效低毒的具有骨组织靶向蓄积特性、用于预防辐射诱导的骨丢失防护剂,已成为预防和减轻辐射对身体健康危害的主要途径之一。但是据我们所知,有关小分子化合物骨丢失防护剂的研究较少。
七甲川菁类小分子是一种传统的有机染料,其最大吸收和发射波长在近红外区(700-900nm),被广泛用于肿瘤的监测及光线治疗(PDT和PTT)。前期,申请人报道了一个新型的七甲川类的有机小分子NIRCP-61,并证实其可以显著提高干细胞对辐射的防护(γ照射,5Gy),但不足之处是该小分子不具有骨靶向蓄积的特性。因此,为了提高其辐射防护效果,降低其对正常组织和器官的毒副作用,迫切需要开发具有较高骨组织靶向性能的新型辐射防护剂。文献调研表明对于非骨靶向蓄积的药物,可通过引入骨靶向配体(双膦酸结构)来达到骨靶向蓄积的目的。基于此,在七甲川花菁小分子中引入骨靶向功能配体,有望实现其骨靶向蓄积性能。同时,该类小分子化合物的辐射防护特性将在预防辐射诱导的骨丢失中具有重要的意义。
发明内容
本发明的目的是提供一种含双磷酸结构的七甲川花菁类小分子化合物及其合成方法,本发明在七甲川花菁类小分子的共轭母体结构中引入具有骨靶向特性的双磷酸结构,构建了一种高选择性识别骨组织、近红外荧光成像的七甲川花菁类小分子化合物。所述七甲川花菁类化合物对辐射诱导的骨丢失具有良好的防治功能,对预防辐射损伤具有重大意义。所述化合物的制备方法简单,还有成本低的优点。
实现本发明的技术方案:
一种含双磷酸结构的七甲川花菁类小分子化合物,其结构如下:
上述的含双磷酸结构的七甲川花菁类小分子化合物的制备方法,有以下步骤:
1)35-45℃下,原料IR-783用有机溶剂1溶解后,搅拌下加入3-巯基丙酸,反应结束后,经过减压浓缩、柱分离纯化后,获得目标化合物含羧基官能团的IR-3Q;
2)室温下,将步骤1)所得含羧基官能团的IR-3Q化合物溶解在有机溶剂2中,并加入缩合剂及活化剂,反应,反应液经抽滤、减压浓缩及干燥,得到活化的中间体化合物IR-3Q;
3)将阿伦磷酸钠用缓冲溶液溶解得溶液a;室温下用乙腈将步骤2)制得的中间体化合物IR-3Q复溶,得溶液b,搅拌下将溶液b分批加入溶液a中,继续搅拌2h,得到含双磷酸结构的七甲川花菁类小分子化合物粗品,经制备液相色谱分离纯化,得纯品IR-ALN。
步骤1)中所述有机溶剂1为甲苯、二氯甲烷、N,N-二甲基甲酰胺(DMF)、二甲基乙酰胺(DMA)的任意一种,优选为N,N-二甲基甲酰胺;
步骤2)中所述有机溶剂2为二氯甲烷、N,N-二甲基甲酰胺(DMF)、二乙醇胺(DEA)、水的任意一种或几种组合的混合溶剂;优选为二氯甲烷。
步骤2)中所述缩合剂为二环己基碳二亚胺(DCC)、二异丙基碳二亚胺(DIC)、1-(3-二甲氨基丙基)-3-乙基碳二亚胺盐酸盐(EDCI)的任意一种;
所述活化剂为4-二甲氨基吡啶(DMAP)、1-羟基苯并三唑(HOBT)、N-羟基琥珀酰亚胺(NHS)的任意一种。
步骤3)中所述分批加入为分三批(次),每批间隔2h。
步骤3)中所述缓冲溶液为磷酸盐缓冲液(pH=7.2)、硼酸缓冲液(pH=8.5)、HEPES缓冲液(pH=8.2)的任意一种,优选地,为硼酸缓冲液(pH=8.5);
上述的七甲川花菁类小分子化合物在制备预防辐射诱导骨丢失的防护剂中的应用。
上述的含双磷酸结构的七甲川花菁类小分子化合物在制备用于骨组织近红外成像的制剂的应用。
申请人实验表明:本发明所述七甲川花菁类小分子化合物,其最大吸收(λmax=776nm)和发射波长(λmax=807)在近红外区(700-900nm),如图3所示,在此波长范围内生物组织自发荧光较弱。
本发明在七甲川花菁小分子中引入骨靶向功能配体,所述小分子化合物具有骨靶向蓄积和骨组织近红外荧光成像的性能,作为一种骨丢失防护剂,用于预防辐射导致的骨丢失。
本发明制备得到的七甲川花菁类小分子化合物具有骨靶向蓄积的特性,同时具有骨组织近红外荧光成像能力,申请人实验表明:本发明制得的七甲川花菁小分子具有骨靶向蓄积的特性,主要分布于椎骨,下肢长骨和下肢膝关节;组织脏器成像显示其主要蓄积在肝脏,肾脏也有部分蓄积。
本发明制得的七甲川花菁类小分子化合物具有良好的辐射防护效应,申请人实验表明:辐照会导致小鼠松质骨骨小梁骨质明显丢失数量明显减少,骨小梁间隙增加,用本发明制备得到的七甲川花菁类小分子化合物处理后,其松质骨骨小梁骨质丢失结构情况得到改善。
下面结合具体实施例,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。下列实施例中未注明具体条件的实验方法,通常按照常规条件或按照制造厂商所建议的条件。
附图说明
图1:IR-3Q的核磁氢谱图(1H NMR)。
图2:IR-ALN的高分辨率质谱图(HRMS)。
图3:IR-ALN水溶液中的吸收及荧光谱图。
图4:IR-ALN的主要脏器及骨组织近红外荧光成像;其中,A为小鼠尾静脉注射IR-ALN 24h后,脏器分布,脏器顺序(自上而下、从左到右)分别为:心脏、肝脏、脾脏、肺、肾脏、小肠和膀胱。
骨组织(B:仰位;C:俯位)及离体股骨胫骨(D)近红外荧光成像情况。
图5:IR-ALN对小鼠大腿股骨的骨丢失的影响,其中,上排:股骨远端剖视图;下排:股骨远端松质骨和皮质骨的3D重建图。
具体实施方式
本实施例采用的试剂均为市售的化学纯试剂。
本实施例中采用的仪器和设备:
所有反应均以薄层层析跟踪,使用烟台市芝罘黄务硅胶开发试验厂所生产的高效薄层层析硅胶板(型号CF-254),磷钼酸、碘化铋钾、溴甲酚绿或硫酸显色。
柱层析用烟台市芝罘黄务硅胶开发试验厂生产的层析硅胶,层析用有机溶剂均为分析纯。
质谱图由高分辨率质谱仪(Waters,Xevo G2-S QTOF)测定;
吸收光谱图由UV-VIS-NIR光谱仪(日本岛津市的UV-3600扫描分光光度计)测定;
荧光光谱图由近红外荧光光谱仪(Thermo Fisher,美国)测定,使用Gallardo专业成像系统进行近红外荧光成像。
实施例1中间体化合物(IR-3Q)的合成
向25mL的圆底反应瓶中原料IR-783(982.9mg),并用12mL的无水DMF溶解。在搅拌下加入3-巯基丙酸(206.7mg),完毕后加热升温至40℃,继续搅拌反应,薄层色谱监测反应。当薄层色谱显示IR-783无剩余后,即停止加热,并自然冷却至室温。经减压蒸馏除去反应溶液中的溶剂得暗红色粘稠物,经硅胶柱层析纯化的墨绿色固体。
IR-3Q:1H NMR(600MHz,DMSO-d):δ8.68,8.66,7.59,7.58,7.42,7.41,7.40,7.40,7.39,7.38,7.37,7.37,7.25,7.25,7.24,7.23,7.22,7.22,6.31,6.29,5.73,4.16,4.15,4.14,3.35,3.34,3.33,3.31,3.05,3.03,3.02,3.01,2.97,2.95,2.94,2.86,2.70,2.63,2.62,2.61,2.51,2.50,2.50,2.49,2.48,2.47,2.47,2.47,2.47,1.81,1.80,1.79,1.76,1.75,1.74,1.73,1.66,1.17,1.15,1.14,1.07,1.06,1.05,0.95,0.94,0.92.(参见图1)。
IR-3Q:HRMS(ESI+):796.29523(M+H+)calcd exact Mass:796.29。
实施例2目标化合物IR-ALN的合成
25mL反应瓶中加入上述制备的化合物IR-3Q(150mg),并加入8mL的二氯甲烷。搅拌溶解后,加入缩合剂二环己基碳二亚胺(DCC,340.4mg)及活化剂N-羟基琥珀酰亚胺(NHS,190mg)。加入完毕后,于20℃下继续搅拌反应12h,有大量白色固体生成。减压抽滤,滤液经减压浓缩后得羧基活化的中间体化合物IR-3Q,该化合物不需要进一步的纯化,即进行下一步的反应。
将阿伦磷酸钠(26mg)用4mL的硼酸缓冲液(pH=8.4)溶解得溶液a。同时,将步骤上述制得的中间体IR-3Q用无水乙腈(2mL)复溶得溶液b。在室温搅拌下,将溶液b分三批加入溶液a中(每批间隔2h)。加入完毕后,反应液继续搅拌2h即可制得目标化合物IR-ALN的粗品。该粗品经制备液相色谱分离纯化,即得含双磷酸结构的化合物IR-ALN纯品。
IR-ALN:HRMS(ESI+):1028.3002;Calcd exact Mass:1027.27(参见图2)。
实施例3 IR-ALN的光学性能测试
将IR-ALN溶于DMSO中,配制得到浓度为10mM的储备液,置于-20℃保存待用;使用前,用磷酸缓冲液(PBS,pH 7.22)稀释得终浓度为2μM的IR-ALN工作液。利用紫外-可见-近红外光谱仪(紫UV-3600扫描分光光度计,日本岛津)测试该溶液得到其吸收光谱;利用近红外荧光光谱仪(美国,Thermo Fisher),在激发波长为740nm,得到发射波长范围为750-900nm的荧光光谱(如图3所示)。
实施例4辐射诱导骨丢失实验
(1)、药物配制
将IR-ALN溶于DMSO中,配制得到浓度为10mM的储备液,置于-20℃保存待用;使用前,用磷酸缓冲液(PBS,pH 7.22)按1:20的比例稀释得到IR-ALN工作液。
(2)、动物实验
正常BLAC/c雄性小鼠随机分为空白对照组、辐照处理组和辐照加药组,各10只。其中,辐照加药组按200uL/只(0.5mg/kg)剂量,尾静脉注射IR-ALN工作液,完毕后常规进食。24h后小鼠进行x-ray照射,辐射剂量为2Gy,剂量率为1.265Gy/min。小鼠常规饲养30天后,脱颈处死,进行主要脏器及骨组织的近红外成像(如图4所示)。
此外,获取后肢股骨组织,4%多聚甲醛固定48h后,更换成70%乙醇,进行microCT扫描分析。小鼠辐照处理30天后的Micro CT图像(如图5所示)。
Claims (8)
1.一种含双磷酸结构的七甲川花菁类小分子化合物,其特征在于,其结构如下:
2.权利要求1所述的含双磷酸结构的七甲川花菁类小分子化合物的制备方法,其特征在于,有以下步骤:
1)35-45℃下,原料IR-783用有机溶剂1溶解后,搅拌下加入3-巯基丙酸,反应结束后,经过减压浓缩、柱分离纯化后,获得含羧基官能团的IR-3Q;
2)将步骤1)所得含羧基官能团的IR-3Q溶解在有机溶剂2中,并加入缩合剂及活化剂,室温下磁力搅拌反应,反应完毕后,溶液经抽滤、减压浓缩及干燥,得到活化的中间体化合物IR-3Q;
所述缩合剂为二环己基碳二亚胺;
所述活化剂为N-羟基琥珀酰亚胺;
3)将阿伦磷酸钠用缓冲溶液溶解得溶液a;所述缓冲溶液为pH=8.5的硼酸缓冲液,室温下用乙腈将步骤2)制得的活化的中间体化合物IR-3Q复溶,得溶液b,搅拌下将溶液b分批加入溶液a中,继续搅拌2h,得到含双磷酸结构的七甲川花菁类小分子化合物粗品,经制备液相色谱分离纯化,得纯品IR-ALN。
3.根据权利要求2所述的方法,其特征在于,步骤1)中所述有机溶剂1为甲苯、二氯甲烷、N,N-二甲基甲酰胺(DMF)、二甲基乙酰胺(DMA)的任意一种;
步骤2)中所述有机溶剂2为二氯甲烷、N,N-二甲基甲酰胺(DMF)、二乙醇胺(DEA)的任意一种或几种组合的混合溶剂。
4.根据权利要求3所述的方法,其特征在于,所述有机溶剂1为N,N-二甲基甲酰胺。
5.根据权利要求3所述的方法,其特征在于,所述有机溶剂2为二氯甲烷。
6.根据权利要求2所述的方法,其特征在于:步骤3)中所述分批加入为分三批加入,每批间隔2h。
7.权利要求1所述的七甲川花菁类小分子化合物在制备预防辐射诱导的骨丢失防护剂中的应用。
8.权利要求1所述的七甲川花菁类小分子化合物在制备用于骨组织靶向近红外成像制剂的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110858109.9A CN113717226B (zh) | 2021-07-28 | 2021-07-28 | 含双磷酸结构的七甲川花菁类小分子化合物和制备方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110858109.9A CN113717226B (zh) | 2021-07-28 | 2021-07-28 | 含双磷酸结构的七甲川花菁类小分子化合物和制备方法及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113717226A CN113717226A (zh) | 2021-11-30 |
CN113717226B true CN113717226B (zh) | 2023-12-22 |
Family
ID=78674215
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110858109.9A Active CN113717226B (zh) | 2021-07-28 | 2021-07-28 | 含双磷酸结构的七甲川花菁类小分子化合物和制备方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113717226B (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106511337A (zh) * | 2016-09-23 | 2017-03-22 | 中国人民解放军第三军医大学 | 一类七甲川吲哚花菁染料的应用 |
-
2021
- 2021-07-28 CN CN202110858109.9A patent/CN113717226B/zh active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106511337A (zh) * | 2016-09-23 | 2017-03-22 | 中国人民解放军第三军医大学 | 一类七甲川吲哚花菁染料的应用 |
Non-Patent Citations (4)
Title |
---|
"Charge and Hydrophobicity Effects of NIR Fluorophores on Bone-Specific Imaging";Kai Bao等;《Theranostics》;第5卷(第6期);第609-617页 * |
"Fluorescent Bisphosphonate and Carboxyphosphonate Probes: A Versatile Imaging Toolkit for Applications in Bone Biology and Biomedicine";Shuting Sun等;《Bioconjugate Chem.》;第27卷;第329-340页 * |
"Novel bisphosphonates near infrared fluorescent and non-fluorescent nanoparticles of narrow size distribution for bone targeting";Nimrod Tal等;《Polymer》;第132卷;第188-192页 * |
"Real-time monitoring and accurate diagnosis of drug-induced hepatotoxicity in vivo by ratio-fluorescence and photoacoustic imaging of peroxynitrite";Hongjun Zhuang等;《Nanoscale》;第12卷;第10216–10225页 * |
Also Published As
Publication number | Publication date |
---|---|
CN113717226A (zh) | 2021-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0255471B1 (de) | 1,4,7,10-Tetraazacyclododecan-Derivate | |
EP0130934B1 (de) | Neue Komplexbildner, Komplexe und Komplexsalze | |
CN1840531B (zh) | 用于肿瘤成像和光动力学疗法的卟啉基化合物 | |
CN104800862A (zh) | 用于核成像和放射疗法的螯合剂的有效合成:组合物和应用 | |
CN1011571B (zh) | 可用于治疗肿瘤的一种药物的制备方法 | |
CN110003461B (zh) | 多碘修饰的氟硼二吡咯类衍生物及其制备方法和应用 | |
CN108070275B (zh) | 方酸染料类化合物、制备方法及用途 | |
JP7043260B2 (ja) | 新規なジヒドロポルフィンe6誘導体及びその薬学的に許容される塩、その調製方法並びに使用 | |
CN105288623B (zh) | 一种用于肿瘤治疗的药物及其制备方法 | |
CN1850779A (zh) | β-榄香烯含氮衍生物及其制备方法和用途 | |
CN109796483B (zh) | 一种水溶性阳离子型光敏剂及其制备和应用 | |
CN109575061B (zh) | 一种水溶性的抗癌光敏剂及其制备和应用 | |
KR102068609B1 (ko) | 광감각제, 광감각제를 포함하는 조성물 및 광역동 치료 방법 | |
WO2023001317A1 (zh) | 基于切伦科夫效应的酸响应纳米胶束及其制备方法和应用 | |
CN113717226B (zh) | 含双磷酸结构的七甲川花菁类小分子化合物和制备方法及应用 | |
US6239145B1 (en) | Nitroxyl compounds and drugs and reagents containing the same as the active ingredient | |
WO2023245857A1 (zh) | 一种辣椒素衍生化光敏剂及其制备方法与应用 | |
CN1146197A (zh) | 环三胺螯合剂 | |
CN1523003A (zh) | 新的2-(α-羟基戊基)苯甲酸盐及其制法和用途 | |
RU2372099C1 (ru) | Иттербиевые комплексы тетрапиразолилпорфиринов как флуоресцентные метки для диагностики злокачественных новообразований | |
CN111671920B (zh) | 一种花菁类光敏剂核酸纳米聚集体的制备及应用 | |
EP2366693A1 (en) | Nitroimidazole-amino acid compound type nuclide hypoxia imaging agent and intermediates for preparing them | |
CN111057063B (zh) | 一种用于急性淋巴细胞白血病的靶向光动力治疗的酞菁衍生物及其制备方法 | |
CN113717183B (zh) | 周环不对称精氨酸修饰酞菁及其制备和在制药领域的应用 | |
CN113304261B (zh) | 一种电荷反转型智能光线诊疗平台的构建及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |